August 12, 2020 -- Vaccibody and Nektar Therapeutics have started a phase I/IIA trial for a personalized cancer DNA vaccine for patients with advanced squamous cell carcinoma of the head and neck.
Patients are receiving a combination of Nektar's CD122-preferential interleukin-2 (IL-2) pathway agonist bempegaldesleukin (bempeg) and Vaccibody's personalized neoantigen cancer vaccine Vb10.Neo. Adding bempeg to Vb10.Neo is intended to drive maximal expansion of vaccine-induced neoantigen-specific T cells for the treatment of cancer, according to the companies.
The vaccine is designed to specifically activate the patient's immune system to tumor-specific antigens while bempeg will expand and proliferate tumor antigen specific T cells in the periphery and the tumor microenvironment.
Copyright © 2020 scienceboard.net